December 21, 2016
Ipsen to sell Exelixis’s cabozantinib in Canada
Exelixis and Ipsen have signed an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development…
Pharmaceuticals, Biotechnology and Life Sciences
Exelixis and Ipsen have signed an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development…